Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999, 2: 29–41.
Colao A, Auriemma RS, Pivonello R, Galdiero M, Lombardi G. Medical consequences of acromegaly: what are the effects of biochemical control? Rev Endocr Metab Disord 2008, 9: 21–31.
Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008, 159: 89–95.
Melmed S, Colao A, Barkan A, et al; Acromegaly Consensus Group. Guidelines for acromegaly management: an update. Clin Endocrinol Metab 2009, 94: 1509–17.
Giustina A, Chanson P, Bronstein MD, et al; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95: 3141–8.
Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. Clin Endocrinol Metab 2001, 86: 4072–7.
Gittoes NJ, Sheppard MC, Johnson AP, Stewart PM. Outcome of surgery for acromegaly — the experience of a dedicated pituitary surgeon. QJM 1999, 92: 741–5.
Swearingen B, Barker FG 2nd, Katznelson L, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Clin Endocrinol Metab 1998, 83: 3419–26.
De P, Rees DA, Davies N, et al. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. Clin Endocrinol Metab 2003, 88: 3567–72.
Attanasio R, Montini M, Valota M, et al. An audit of treatment outcome in acromegalic patients attending our center at Bergamo, Italy. Pituitary 2008, 11: 1–11.
Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol 2004, 151: 439–46.
Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure’. Eur J Endocrinol 2005, 152: 379–87.
Bex M, Abs R, T’Sjoen G, et al. AcroBel-the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol 2007, 157: 399–409.
Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004, 89: 2789–96.
Abosch A, Tyrrell JB, Lamborn KR, Hannegan LT, Applebury CB, Wilson CB. Transsphenoidal microsurgery for growth hormone-secreting pituitary adenomas: initial outcome and long-term results. J Clin Endocrinol Metab 1998, 83: 3411–8.
Kreutzer J, Vance ML, Lopes MB, Laws ER Jr. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 2001, 86: 4072–7.
Fukuda I, Hizuka N, Murakami Y, et al. Clinical features and therapeutic outcomes of 65 patients with acromegaly at Tokyo Women’s Medical University. Intern Med 2001, 40: 987–92.
Murray RD, Peacey SR, Rahim A, Toogood AA, Thorner MO, Shalet SM. The diagnosis of growth hormone deficiency (GHD) in successfully treated acromegalic patients. Clin Endocrinol (Oxf) 2001, 54: 37–44.
de Boer H, Roelfsema F, Frölich M, Kamphuisen HA, van Seters AP. Plasma growth hormone profiles and sleep: a study of 13 treated acromegalics. Clinical Endocrinology 1989, 30: 251–61.
Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102–52.
Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 2010, 72: 203–8.
Melmed S. Acromegaly. N Engl J Med 2006, 355: 2558–73.